Oppenheimer analyst Jay Olson raised his price target on Neurocrine
shares to $110 from $100, citing the positive Phase 3 study results for elagolix in the treatment of uterine fibroids by Neurocrine
's collaborator AbbVie (ABBV).
Biotechnology company Neurocrine
Biosciences Inc (NASDAQ:NBIX) said on Wednesday that it will proceed with plans to file the NDA for opicapone for Parkinson's disease during the first half of 2019 based on existing pivotal clinical trial data.
Product Pipeline Review - 2015', provides an overview of the Neurocrine
Shares of Neurocrine
Biosciences closed the week up 4 cents at $5.
intends to initiate clinical studies after submission of an investigational new drug application in the first half of 2008.
Unlike these agents, which are already on the market, indiplon was designed to have a very short half-life, according to its developer, Neurocrine
Unlike these agents, which are on the market, indiplon was designed to have a very short half-life, according to its developer, Neurocrine
With the initiation of this trial, Neurocrine
now has five clinical development programs including insomnia, malignant glioma, diabetes and multiple sclerosis with two additional compounds planned to enter new Phase I studies in 2001.
HAY209) GARY LYONS, CEO of NEUROCRINE
BIOSCIENCES INC (NBIX), describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward.
Biosciences Inc (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced yesterday that it has named Eiry W Roberts, MD as its new chief medical officer, effective 8 January 2018, to replace Christopher O'Brien, MD who is retiring from the role.
The notes will be senior unsecured obligations of Neurocrine
and will accrue interest payable semiannually in arrears.